Zephyr Platform: Transforming Complex Data into Actionable Insights

We value your privacy

We use cookies to enhance your browsing experience, serve personalised ads or content, and analyse our traffic. By clicking "Accept All", you consent to our use of cookies.

Powered by

Zephyr Platform: Transforming Complex Data into Actionable Insights

Built for Real-World Impact

The Zephyr Platform combines multi-modal AI, enterprise-scale real-world data, and deeply profiled oncology cohorts—delivered on secure, compliant infrastructure built for speed and scale. Our solutions integrate seamlessly into partner workflows to de-risk development, optimize patient selection, and accelerate clinical translation—driving solutions from discovery to deployment.

AIM Suite: Multi-Modal AI for Precision Oncology

Flexible AI modules tailored to partner needs—real-world validated, interpretable, and ready to deploy.

The AIM Suite is a set of modular, biologically interpretable AI tools designed to integrate seamlessly into R&D workflows—no new assays required. Each module can operate independently or be combined, giving partners the flexibility to tailor solutions to their drug development or clinical needs.

Predict response to small molecules or immune checkpoint inhibitors using clinically available data. Validated in real-world cohorts, outperforming conventional biomarkers, and adaptable as AI-CDx for partner drugs.

Fine-tuned companion diagnostics co-developed with biopharma and diagnostics partners. Built on AIM-Bx and adapted to partner assays and assets with preclinical or clinical data.

Reconstructs mRNA expression from DNA-based LDTs and minimal clinical data with high concordance to RNAseq. Enhances interpretability and feeds downstream models with biologically rich expression-level inputs.

Nexus: Real-World Intelligence at Scale

Linking multimodal real-world data to discovery, validation, and market strategy.

Nexus transforms EHR, claims, genomics, and pathology data into actionable insights for discovery, validation, and market strategy.

Extract intelligence from 90M+ patients across oncology (1M+ with NGS) and chronic disease.

Define fit-for-purpose populations and credible comparator arms for trials and HEOR.

Train, test, and refine predictive models on linked longitudinal data.

Predict outcomes and costs to inform pricing, access, and value-based care strategies.

Deep Oncology Data: Curated, Consented Cancer Cohorts

One of the world’s largest deeply profiled oncology resources, enabling discovery and validation at scale.

Through Aster Insights™ and the ORIEN Total Cancer Care® study, Zephyr provides access to one of the largest and most deeply profiled oncology resources in the world—400K+ lifetime-consented patients across leading cancer centers.

Aster Avatar: matched clinical, exome, transcriptome, and digital pathology data with longitudinal updates–ideal for translational research and biomarker discovery.

Generate new molecular data to power discovery, validation, and regulatory programs.

Enterprise-Grade Infrastructure for Speed and Scale

Built for pharma-grade security and speed—SOC 2 & HIPAA compliant, fast to pilot, and scalable to impact.

Zephyr is built to meet the highest standards of security, compliance, and scalability—going far beyond academic or point-solution approaches. With SOC 2 and HIPAA compliance, partner data is handled securely and responsibly.

Our investment in these systems means models move seamlessly from concept to production.

Zephyr can launch proof-of-concept pilots in weeks and scale them to clinical and commercial applications without re-engineering.

The Power of Our Platform, Tailored to You

Zephyr’s platform bridges experimental and clinical domains, extracting hidden signals from large multi-modal datasets to deliver actionable insights that drive discovery, validation, and co-development. Partners benefit from models enriched with deep biological context—shaped by learnings across vast drug, tumor, and patient landscapes—yet adaptable and fine-tunable to their unique assets.

  • Clinically validated across diverse, real-world patient cohorts
  • Seamlessly compatible with existing diagnostics—no new assays required
  • Biologically interpretable outputs that support trust and regulatory alignment
  • Flexible and adaptable—retrospective or prospective validation, fine-tuned to partner drugs or LDTs
  • Fast to start, scalable to impact—pilots launch in weeks
Partner With Us